Amphastar Pharmaceuticals reported third quarter 2026 revenue of US$207.61 million and net income of US$37.76 million, with adjusted earnings per share and sales both coming in ahead of consensus expectations. Record contributions from BAQSIMI and Primatene Mist, together with expanded authorization for the share repurchase program, highlighted management’s focus on higher margin products and capital return. This article examines how Amphastar Pharmaceuticals’ investment narrative is...
Amphastar (AMPH) delivered earnings and revenue surprises of +46.15% and +6.72%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Amphastar is rated a Hold, and shares have dropped over 40%, now trading at ~$26.5 with a $1.1bn market cap. Read more on AMPH stock here.
Let’s dig into the relative performance of Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers as we unravel the now-completed Q2 generic pharmaceuticals earnings season.
Recent Price Moves Put Amphastar Pharmaceuticals in Focus Amphastar Pharmaceuticals (AMPH) has drawn fresh attention after recent share price swings, with the stock closing at $23.18 and showing mixed performance over the past week, month, past 3 months, and year. Short term, Amphastar Pharmaceuticals has seen momentum build, with a 30-day share price return of 11.55% and a 90-day share price return of 19.55%. Yet the 1-year total shareholder return is down 21.21%, pointing to a recovery that...
Amphastar Pharmaceuticals stock presents a tricky mix for investors, with a steep 3 year share price decline set against valuation checks that now lean cheap on traditional multiples. Over the past 3 years the share price has fallen about 53.6%, which leaves current holders facing a deep drawdown and raises the question of whether the stock has been pushed too far down. Future expectations for Amphastar Pharmaceuticals around the durability of its product portfolio and its ability to convert...
Amphastar Pharmaceuticals, Sandoz and Viatris are positioned to benefit from new launches, biosimilars and a shift toward higher-value generics.
This is the newest page. Registered accounts read further back.